virus
classic
hepatotrop
virus
hepat
e
may
caus
hepat
injuri
among
epsteinbarr
viru
ebv
cytomegaloviru
cmv
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
human
herp
virus
hhv
human
parvoviru
adenovirus
tabl
clinic
present
infect
virus
may
indistinguish
associ
infect
classic
hepatotrop
virus
present
rang
mild
transient
elev
aminotransferas
acut
hepat
liver
liver
failur
virus
consid
possibl
etiolog
agent
patient
acut
liver
injuri
whose
serolog
marker
classic
hepatotrop
virus
indic
activ
infect
present
chapter
review
clinic
manifest
potenti
immunemedi
liver
injuri
associ
sever
virus
see
summari
tabl
viru
establish
differ
form
infect
cell
entri
transloc
ebv
particl
nucleu
confi
rmed
detect
ebv
genom
isol
nuclei
b
cell
oropharynx
may
primari
site
infect
rest
memori
b
cell
thought
site
persist
ebv
throughout
bodi
ebv
evolv
sever
strategi
evad
immun
system
recognit
establish
latent
infect
memori
b
cell
resid
lifelong
without
consequ
major
individu
infect
b
lymphocyt
linear
ebv
genom
becom
circular
form
episom
usual
remain
latent
b
cell
ten
viral
protein
express
latent
infect
b
cell
vitro
limit
gene
express
latenc
ensur
success
escap
cytotox
lymphocyt
ctl
recognit
ebv
share
tendenc
establish
latenc
host
herp
virus
viral
replic
spontan
activ
small
percentag
latent
infect
b
cell
ebv
infect
common
lifelong
infect
affect
human
worldwid
viru
replic
nasopharyng
epitheli
cell
seroposit
person
activ
shed
viru
saliva
transmiss
ebv
usual
occur
contact
oral
secret
diagnosi
ebv
infect
base
clinic
featur
laboratori
serolog
fi
nding
indic
recent
infect
common
leukocytosi
appear
case
predominantli
lymphocytosi
monocytosi
well
mild
thrombocytopenia
affect
individu
ebvspecifi
c
igg
igm
antibodi
direct
viral
capsid
antigen
vca
earli
antigen
ebv
antid
antir
nuclear
antigen
ebvna
solubl
complementfi
xing
antigen
anti
use
viral
detect
monospot
test
detect
heterophil
antibodi
sensit
specifi
c
vast
major
case
indic
liver
biopsi
perform
may
portal
sinusoid
mononuclear
cell
infi
ltration
focal
hepat
necrosi
fatti
infi
ltration
specifi
calli
diagnosi
ebv
hepat
establish
base
combin
elev
aminotransferas
serolog
compat
activ
ebv
infect
typic
fi
nding
liver
biopsi
demonstr
presenc
viral
genom
liver
tissu
variou
molecular
method
imbal
equilibrium
viru
host
immun
system
lead
develop
liver
damag
ebvinfect
patient
ebv
also
involv
develop
tumor
lymphoprolif
disord
hodgkin
lymphoma
burkitt
lymphoma
nasopharyng
carcinoma
demonstr
immunotherapeut
approach
effect
cancer
patient
support
role
immun
system
diseas
pathogenesi
context
ebvrel
tumor
express
viral
antigen
malign
cell
make
suitabl
target
immun
therapi
infus
ebvspecifi
c
ctl
prove
safe
effect
induc
protect
antivir
immun
lack
ebvassoci
malign
innat
adapt
arm
immun
system
play
role
antiebv
immun
ebv
interact
nk
cell
neutrophil
monocyt
macrophag
well
epitheli
cell
relev
viral
resist
tonsil
primari
site
ebv
infect
ebv
trigger
monocyt
tlr
induc
matur
dc
activ
bright
nk
cell
via
nk
cell
hamper
pathogen
entri
mucos
site
thu
restrict
ebv
infect
adapt
immun
establish
viral
immun
control
secret
dcactiv
nk
cell
associ
delay
latent
ebv
antigen
express
inhibit
bcell
transform
decreas
prolifer
fi
rst
week
follow
infect
also
promot
ebvspecifi
c
adapt
immun
respons
favor
earli
primari
viral
infect
nk
cell
thought
limit
viral
burden
virusspecifi
c
cell
abl
elimin
infect
maintain
viral
titer
low
level
innat
immun
use
sever
pattern
recognit
receptor
sens
pathogenassoci
molecular
pattern
pamp
tolllik
receptor
tlr
activ
downstream
effect
primari
ebv
infect
favor
viral
latenc
reactiv
facilit
immun
control
intact
viral
particl
recogn
membran
surfac
receptor
follow
viral
entri
cell
viral
dna
recogn
dual
interact
cell
membran
intracellular
lead
rapid
product
initi
effect
antivir
immun
innat
lymphocyt
also
play
role
resist
ebvassoci
malign
mutat
sap
signalinglymphocyt
activationmolecul
slam
associ
protein
associ
loss
ebvspecifi
c
immun
control
ebv
latenc
viru
develop
mechan
immun
escap
innat
immunitydepend
mechan
includ
inhibit
nk
cell
activ
ebvinduc
gene
ebvtransform
b
lymphocyt
express
high
level
protein
immunosuppress
activ
ebv
genom
also
detect
nonb
cell
includ
phagocyt
monocyt
macrophag
involv
uptak
small
vesicl
call
exosom
contain
viral
mrna
exosom
play
role
earli
phase
ebv
infect
also
involv
innat
immunityrel
cell
type
target
viru
increas
neutrophil
observ
initi
phase
ebv
infect
wherea
transient
episod
acut
neutropenia
often
observ
infecti
mononucleosi
im
third
week
ill
infect
neutrophil
rapidli
die
apoptosi
secret
variou
cytokin
chemokin
eg
reactiv
superoxid
anion
promot
develop
ebvspecifi
c
immun
upregul
induct
apoptosi
neutrophil
inhibit
antiebv
immun
respons
episod
monocytopenia
observ
acut
phase
im
patient
ebvassoci
malign
show
defi
cienci
monocytemedi
adcc
suggest
monocyt
function
affect
cours
ebv
infect
also
demonstr
reduc
phagocyt
activ
observ
ebvinfect
monocyt
ebv
infect
inhibit
function
abil
macrophag
respond
bacteri
challeng
reduc
phagocyt
potenti
inhibit
differenti
monocyt
matur
dc
ebv
temporarili
halt
onset
immun
respons
primari
infect
enabl
effi
cient
viral
replic
permit
accumul
larg
pool
virusinfect
b
lymphocyt
allow
access
viru
memori
bcell
compart
interf
function
dc
initi
virusspecifi
c
immun
modifi
profi
le
secret
cytokin
thu
creat
favor
environ
viral
propag
ctl
major
determin
control
acut
ebv
infect
direct
lytic
latent
antigen
half
total
cell
acut
infect
specifi
c
singl
lytic
ebv
epitop
epitopespecifi
c
cell
activatedmemori
phenotyp
late
stage
infect
frequenc
epitopespecifi
c
cell
direct
latent
ebv
protein
select
increas
confi
rming
ctl
import
cell
limit
infect
convalesc
phase
viru
infect
lytic
infect
viru
express
full
complement
immediateearli
earli
late
lytic
cycl
protein
capabl
replic
within
host
cell
latent
infect
viru
express
fewer
protein
replic
abl
persist
within
host
cell
ebv
develop
abil
rapidli
promot
express
gene
simultan
shut
transcript
program
host
cell
level
increas
im
patient
indic
import
ongo
antivir
respons
howev
entir
viru
inhibit
secret
monocyt
macrophag
ebv
downregul
mrna
transcript
via
suppress
action
transcript
level
ebv
protein
also
modul
ifn
signal
effect
promot
viral
persist
may
also
contribut
tumor
develop
ebv
reactiv
associ
increas
specifi
c
ctlrespons
lytic
ebv
epitop
lead
ebvassoci
chronic
hepat
ebv
reactiv
patient
base
increas
percentag
termin
differenti
cell
suggest
chronic
antigen
stimul
diminish
express
costimulatori
molecul
compromis
reactiv
make
cell
resist
apoptosi
tcell
pool
low
express
low
abil
control
reactiv
viru
typic
fi
nding
elderli
group
similar
chang
found
younger
patient
chronic
cmv
ebv
antigen
stimul
cellular
immun
fundament
control
primari
persist
phase
ebv
propag
humor
respons
control
viral
spread
late
phase
infect
ebv
stimul
strong
humor
respons
lytic
cycl
protein
igm
develop
igg
respons
nucleocapsid
envelop
protein
detect
primari
ebv
infect
igg
respons
immediateearli
earli
lytic
cycl
protein
latent
protein
also
detect
togeth
neutral
antibodi
direct
variou
clinic
condit
associ
ebv
includ
infecti
mononucleosi
burkitt
lymphoma
nasopharyng
carcinoma
hodgkin
diseas
peripher
tcell
lymphoma
posttranspl
lymphoprolif
disord
ptld
primari
ebv
infect
take
place
oropharyng
region
viru
convey
saliva
droplet
infect
individu
primari
infect
lead
transient
viremia
follow
strong
tcell
adapt
immun
respons
hold
infect
latent
immunocompet
individu
infect
delay
adolesc
adulthood
caus
infecti
mononucleosi
im
selfresolv
lymphoid
disord
larg
result
uncontrol
tcell
reaction
direct
ebvinfect
cell
im
patient
ebv
exclus
found
b
blast
prolifer
infl
uenc
latent
gene
follow
resolut
primari
infect
ebv
establish
lifelong
persist
memori
b
cell
viru
remain
clinic
silent
bcell
reservoir
viral
express
entir
repress
process
describ
true
latenc
short
episod
spontan
reactiv
consequ
viral
replic
normal
occur
healthi
individu
manifest
liver
involv
immunocompet
host
rang
mild
selflimit
acut
hepat
occasion
report
fatal
acut
fulmin
hepat
abnorm
liver
blood
test
common
ebv
infect
occur
patient
symptomat
hepat
rare
jaundic
present
case
typic
rise
aminotransferas
gradual
reach
peak
lower
encount
acut
viral
hepat
diagnosi
suggest
presenc
lymphocytosi
andor
splenomegali
compar
im
usual
affect
young
patient
ebv
hepat
usual
affect
older
age
group
recent
review
nearli
case
england
patient
age
year
clinic
biochem
jaundic
lymphocytosi
splenomegali
classic
symptom
im
symptom
last
median
week
patient
requir
brief
hospit
sever
cholestat
jaundic
right
upper
quadrant
abdomin
pain
could
mistaken
bile
duct
obstruct
may
occur
elderli
patient
set
indirect
hyperbilirubinemia
result
ebvassoci
autoimmun
hemolyt
anemia
commonli
caus
jaundic
viralinduc
cholestasi
occasion
clinic
set
ebv
liver
involv
includ
posttransfus
hepat
granulomat
hepat
fatal
fulmin
hepat
ebv
superinfect
may
occur
patient
preexist
autoimmun
hepat
result
sever
hepat
decompens
case
liver
failur
describ
immunocompromis
immunocompet
host
viral
replic
may
caus
signifi
cant
clinic
entiti
sever
complic
patient
diminish
cellmedi
immun
chronic
ebv
hepat
immunecompet
patient
suggest
sever
studi
howev
ebv
detect
human
hepatocyt
specifi
c
latent
antigen
well
eber
transcript
detect
infi
ltrate
ctl
impli
hepatocyt
suffer
collater
damag
chronic
hepat
might
also
induc
solubl
fasligand
activ
cell
trap
liver
via
specifi
c
adhes
molecul
express
kupffer
cell
sinusoid
endotheli
cell
suggest
reactiv
lead
liver
damag
occur
whether
infect
lymphocyt
incident
intent
liver
chronic
activ
ebv
infect
caebv
may
result
disturb
hostviru
balanc
misbal
may
associ
aggress
clinic
cours
caebv
defi
ned
chronic
sever
ill
begin
primari
ebv
infect
associ
elev
transaminas
abnorm
ebv
serolog
suggest
histopatholog
featur
detect
viral
genom
liver
tissu
evid
recurr
ebv
reactiv
increas
circul
ebvspecifi
c
ctl
increas
bcell
express
along
increas
ldh
level
mild
splenomegali
thrombocytopenia
support
diagnosi
caebv
may
also
progress
chronic
recurr
imlik
diseas
western
countri
caebv
milder
asian
countri
mild
form
character
intact
immun
control
b
cell
rel
low
viremia
ebvspecifi
c
ctl
expans
compar
seroposit
donor
patient
iatrogen
congenit
acquir
immunodefi
cienci
increas
risk
ebvassoci
lymphoma
caebv
immun
senesc
elderli
also
associ
reactiv
neoplast
ebvdriven
lymphoprolif
disord
ebv
may
also
trigger
autoimmun
hepat
chronic
granulomat
hepat
vanish
bile
duct
syndrom
exist
acut
mononuclear
hepat
primari
ebv
infect
accept
skeptic
express
hypothesi
ebv
caus
chronic
liver
diseas
immunecompet
patient
ebv
set
may
refer
incident
viru
refl
ect
coinfect
hepatotrop
virus
like
caus
chronic
liver
diseas
amplifi
cation
ebv
genom
circul
b
cell
turn
liver
patient
chronic
liver
diseas
caus
major
hepatotrop
viru
coebv
infect
suggest
cohort
patient
chronic
hepat
b
c
patient
reactiv
ebv
infect
lower
level
hbv
dna
higher
mean
valu
serum
hepat
c
viru
hcv
rna
respect
compar
ebv
patient
without
reactiv
ebv
reactiv
may
preced
hbv
fl
are
reactiv
ebvspecifi
c
cell
promot
product
sever
cytokin
interleukin
il
ebv
share
high
sequenc
homolog
exogen
enhanc
hcv
replic
promot
hcv
replic
inhibit
hbv
replic
absenc
cell
necrosi
tcell
crossactiv
may
also
explain
hbv
hcv
reactiv
ptld
spectrum
lymphoprolif
diseas
occur
posttransplant
set
ebv
infect
main
caus
ptld
incid
ptld
rang
risk
factor
develop
ptld
includ
ebvseroneg
time
transplant
type
organ
transplant
highest
lung
heart
lowest
liver
kidney
recipi
level
type
immun
suppress
specifi
calli
antitcel
immunosuppress
ptld
complic
pediatr
liver
graft
recipi
mortal
pediatr
popul
posttranspl
primari
infect
within
month
olt
associ
sustain
ebv
detect
increas
risk
late
occurr
ptld
ptld
emerg
either
recipi
donor
origin
depend
type
transplant
bone
marrow
transplant
bmt
patient
develop
ptld
donor
origin
ebvinfect
b
cell
deriv
donor
marrow
prolifer
lymphoma
convers
solid
organ
transplant
patient
develop
ptld
recipi
origin
ebv
releas
transplant
organ
infect
recipi
b
cell
spectrum
ptld
rang
polymorph
lymphocyt
prolifer
highgrad
lifethreaten
monoclon
lymphoma
interplay
ebv
life
cycl
latenc
nonvir
factor
determin
histolog
clinic
present
diseas
major
ptld
bcell
origin
ebv
vitro
transform
abil
distinct
latenc
clonal
within
malign
cell
determin
biolog
diseas
measur
viral
load
quantit
polymeras
chain
reaction
pcr
assist
surveil
diagnosi
ptld
although
specifi
citi
diagnosi
posttransplant
patient
monitor
ebv
pcr
level
peripher
blood
purpos
detect
activ
ebv
infect
earli
institut
preemptiv
therapi
prior
develop
overt
ptld
manag
option
ptld
includ
reduct
immun
suppress
biolog
therapi
antib
cell
antibodi
combin
chemotherapi
adopt
immunotherapi
use
ebvspecifi
c
ctl
surgeri
may
consid
local
ptld
reduct
immun
suppress
alon
result
clinic
remiss
adult
pediatr
ptld
patient
restor
ebvspecifi
c
immun
patient
monitor
close
acut
allograft
reject
newer
immunosuppress
includ
mycophenol
mofetil
sirolimu
appear
associ
fewer
posttranspl
malign
patient
xlink
lymphoprolif
disord
xlp
approxim
may
develop
sever
form
im
hemophagocyt
lymphohistiocytosi
fulmin
hepat
treatment
consist
etoposidebas
chemotherapi
hematopoiet
stem
cell
transplant
earli
treatment
primari
ebv
infect
patient
prior
develop
hlh
may
compris
treatment
antibodi
combin
antivir
acyclovir
ganciclovir
ivig
steroid
ebv
consid
major
factor
develop
wide
rang
cancer
immunocompet
immunocompromis
individu
ebv
infect
cell
clone
promot
replic
hcv
suggest
involv
develop
hepatocellular
carcinoma
hcc
ebvinfect
cell
support
hcv
replic
better
uninfect
cell
suggest
ebv
may
act
helper
viru
promot
hcv
replic
hcvposit
hcc
greater
amount
ebv
dna
report
hcvposit
hcc
compar
hbvassoci
hcc
studi
liver
cancer
found
harbor
ebv
dna
fi
nding
howev
confi
rmed
studi
possibl
sourc
detect
ebv
dna
might
infi
ltrate
lymphocyt
weak
posit
ebv
dna
liver
tissu
explain
other
possibl
amplifi
cation
ebv
dna
lymphoid
infi
ltrate
blood
refl
ect
high
ebv
dna
load
patient
primari
ebv
infect
subclin
major
immunocompet
individu
may
lead
im
adolesc
adult
gener
selflimit
therefor
immunocompet
individu
symptomat
treatment
alon
recommend
includ
rest
adequ
hydrat
nutrit
analges
antipyret
need
patient
suffer
im
avoid
exert
particip
sport
recommend
least
week
due
rare
risk
splenic
ruptur
rare
patient
suffer
sever
complic
acut
ebv
usual
treat
corticosteroid
even
though
littl
evid
support
use
dose
use
vari
differ
report
use
antivir
manag
sever
ebv
infect
immunocompet
host
debat
howev
suggest
adjunct
steroid
treatment
especi
case
refractori
diseas
sever
antivir
drug
includ
acycl
nucleosid
nucleotid
analogu
pyrophosph
analogu
inhibit
replic
ebv
cell
cultur
via
inhibit
ebv
dna
polymeras
acyclovir
inhibit
vitro
ebv
replic
transient
reduc
viral
shed
oropharynx
reduc
viremia
symptom
ganciclovir
effect
treatment
ebv
hepat
small
number
children
adult
valganciclovir
oral
prodrug
ganciclovir
success
use
treatment
sever
acut
ebv
hepat
mg
day
addit
drug
antivir
activ
ebv
includ
valacyclovir
famciclovir
foscarnet
patient
acut
liver
failur
consid
urgent
liver
transplant
likelihood
spontan
recoveri
small
patient
immunodefi
cienci
increas
risk
liver
failur
develop
lethal
lymphoprolif
diseas
major
pathogen
caus
thought
import
develop
lymphoprolif
disorderslymphoma
primari
immunodefi
cienci
xlp
ataxia
telangiectasia
wiskottaldrich
syndrom
chediakhigashi
syndrom
scid
cvid
other
immunosuppress
therapi
hivaid
patient
primari
ebv
infect
treat
preemptiv
ex
vivogener
ebvspecifi
c
ctl
effect
antivir
medic
seroneg
patient
xlp
monthli
prophylaxi
ivig
recommend
patient
develop
ebvassoci
lymphoprolif
diseas
may
benefi
chemotherapi
radiat
therapi
biolog
therapi
monoclon
antibodi
ebvspecifi
c
ctl
hematopoet
stem
cell
transplant
potenti
cur
therapi
mani
patient
usual
recommend
children
human
cmv
doublestrand
dna
viru
largest
member
beta
herpesvirida
famili
cellular
respons
cmv
infect
character
cytomegali
spectrum
promin
clinic
syndrom
spectrum
clinic
syndrom
associ
cmv
diseas
rang
asymptomat
infect
lifethreaten
congenit
cmv
syndrom
neonat
infecti
mononucleosi
syndrom
young
adult
sever
pulmonari
retin
neurolog
gastrointestin
hepat
diseas
immunocompromis
host
infect
acquir
either
perinat
period
infanc
adulthood
sexual
contact
blood
transfus
organ
transplant
serolog
studi
cmvigm
antibodi
help
diagnosi
primari
infect
viral
cultur
techniqu
use
shell
vial
assay
cmv
earli
antigen
molecular
techniqu
detect
cmv
earli
antigen
cmv
dna
increas
sensit
detect
cmv
infect
blood
end
organ
tissu
clearli
establish
diagnosi
activ
cmv
infect
necessari
histolog
evid
cellular
injuri
associ
infect
distinct
patholog
fi
nding
liver
biopsi
import
diagnosi
cmv
hepat
especi
immunocompromis
host
giant
multinucl
cell
reaction
infl
ammatori
respons
multifoc
necrosi
biliari
stasi
common
larg
nuclear
inclusionbear
cell
socal
owl
eye
inclus
detect
hepatocyt
bile
duct
epithelium
seropreval
cmv
worldwid
rang
primari
cmv
infect
immunocompet
adult
asymptomat
associ
mild
im
syndrom
symptomat
cmv
infect
nonimmunocompromis
host
tradit
consid
display
benign
selflimit
cours
diseas
resembl
ebvim
syndrom
similar
herp
virus
primari
infect
resolv
enter
lifelong
latenc
live
virus
sequest
nonrepl
state
person
latent
infect
intact
immun
system
symptom
exhibit
antibodi
cmv
circul
lymphocyt
monocyt
polymorphonuclear
leukocyt
may
serv
reservoir
site
viral
latenc
risk
intermitt
reactiv
increas
immunosuppress
liver
dysfunct
commonli
associ
cmv
mononucleosi
usual
mild
rare
symptomat
immunocompet
patient
hepatosplenomegali
laboratori
evid
mild
moder
elev
liver
enzym
predomin
featur
increas
aminotransferas
alkalin
phosphatas
major
case
level
lower
encount
acut
hepat
due
classic
hepat
virus
rare
manifest
cmv
hepat
includ
tender
hepatomegali
granulomat
hepat
anicter
icter
cholestat
hepat
acut
hepat
massiv
necrosi
morbid
mortal
cmv
infect
may
caus
immunocompet
host
recent
review
patient
sever
cmv
infect
affect
almost
everi
system
gastrointestin
tract
gastroenter
duoden
ileiti
coliti
proctiti
central
nervou
system
mening
enceph
transvers
myeliti
nerv
palsi
myeloradiculopathi
frequent
site
addit
hematolog
manifest
hemolyt
anemia
thrombocytopenia
ocular
uveiti
retin
liver
hepat
pulmonari
pneumon
thrombosi
arteri
venou
system
deep
venou
thrombosi
portal
vein
thrombosi
pulmonari
embol
describ
sever
case
treat
ganciclovir
valganciclovir
fatal
outcom
despit
therapi
special
popul
affl
ict
cmv
diseas
consist
patient
preexist
infl
ammatori
bowel
diseas
frequent
elev
patient
may
promot
reactiv
latent
cmv
infect
promot
addit
cytokin
releas
particularli
turn
lead
viciou
circl
exacerb
infl
ammatori
bowel
diseas
sequenc
event
may
observ
patient
infl
ammatori
bowel
diseas
recent
receiv
steroid
treatment
cmv
coliti
patient
underli
infl
ammatori
bowel
diseas
potenti
lead
sever
complic
includ
toxic
megacolon
coloves
fi
stula
perfor
periton
immunocompromis
patient
cmv
diseas
result
either
primari
infect
commonli
reactiv
latent
infect
dissemin
cmv
infect
immunocompromis
patient
impair
cellmedi
immun
includ
hivinfect
patient
transplant
recipi
congenit
infect
patient
associ
increas
morbid
mortal
anticmv
antibodi
detect
episod
reactiv
howev
incid
sever
cmv
diseas
close
parallel
degre
cellular
immun
dysfunct
character
decreas
number
ctl
natur
killer
cell
clinic
syndrom
observ
patient
includ
enceph
pneumon
hepat
uveiti
retin
coliti
graft
reject
cmv
infect
affect
human
embryo
host
immatur
immunolog
respons
may
lead
seriou
complic
microcephali
mental
retard
spastic
paralysi
hepatosplenomegali
anemia
thrombocytopenia
deaf
optic
nerv
atrophi
lead
blind
cmv
common
opportunist
viral
infect
aid
patient
caus
retin
central
nervou
system
infect
esophag
coliti
cmv
may
also
invad
hepatobiliari
tract
aid
patient
caus
hepat
pancreat
acut
acalcul
cholecyst
presenc
cmv
retin
gastrointestin
diseas
viremia
aid
patient
increas
risk
cholestat
syndrom
caus
papillari
stenosi
scleros
cholang
aid
cholangiopathi
usual
respond
antivir
therapi
hepat
frequent
organspecifi
c
complic
cmv
infect
liver
transplant
affect
recipi
higher
incid
among
seroneg
recipi
seroposit
patient
vs
respect
case
infect
occur
consequ
reactiv
rather
primari
infect
current
opinion
cmv
infect
immunocompet
patient
requir
treatment
data
need
antivir
treatment
immunocompet
patient
sever
cmv
infect
confl
ict
improv
observ
treat
patient
may
relat
typic
selflimit
cours
diseas
thu
attribut
certainti
treatment
effect
sever
case
particularli
patient
impair
cellmedi
immun
therapi
lifesav
drug
approv
treatment
cmv
diseas
includ
ganciclovir
valganciclovir
foscarnet
cidofovir
ganciclovir
consid
antivir
agent
choic
cmv
durat
therapi
guid
repeat
measur
cmv
blood
sampl
emerg
strain
resist
ganciclovir
pose
therapeut
challeng
foscarnet
cidofovir
may
becom
altern
antivir
agent
valganciclovir
recent
evalu
among
liver
transplant
recipi
cmv
diseas
ganciclovir
lead
myelosuppress
central
nervou
system
disord
hepatotox
irrevers
infertil
teratogenesi
wherea
foscarnet
caus
disturb
miner
electrolyt
homeostasi
nephrotox
longterm
administr
agent
may
lead
emerg
resist
viral
strain
cmv
infect
common
complic
follow
liver
transplant
contribut
morbid
mortal
patient
cmv
evad
immun
system
result
state
latenc
sever
type
host
cell
cellular
site
viral
latenc
becom
reservoir
reactiv
period
stress
cytokin
releas
serv
vehicl
transmiss
suscept
host
pharmacolog
induc
impair
immun
respons
endogen
reactiv
allografttransmit
cmv
lead
febril
tissueinvas
diseas
liver
transplant
recipi
overal
liver
transplant
recipi
develop
cmv
diseas
lack
preexist
cmvspecifi
c
immun
cmvseroneg
recipi
liver
allograft
cmvseroposit
donor
cmv
expos
patient
highest
risk
cmv
diseas
complic
cmv
vs
cmvseroposit
recipi
cmv
r
incid
reduc
liver
transplant
recipi
receiv
antivir
prophylaxi
valganciclovir
oral
ganciclovir
fi
rst
month
follow
liver
transplant
cmv
diseas
rate
highrisk
cmv
less
cmv
r
report
patient
receiv
antivir
prophylaxi
recent
random
control
trial
show
day
prophylaxi
effect
day
therapi
highrisk
patient
howev
yet
becom
standard
recommend
due
safeti
cost
individu
receiv
antivir
prophylaxi
cmv
diseas
may
occur
month
complet
antivir
prophylaxi
henc
term
delayedonset
lateonset
cmv
diseas
use
highli
potent
pharmacolog
immun
suppress
sever
impair
abil
liver
transplant
recipi
mount
effect
immun
respons
reactiv
cmv
therebi
predispos
increas
risk
cmv
diseas
sever
immun
dysfunct
strongest
lymphocytedeplet
drug
antithymocyt
globulin
defect
innat
cmvspecifi
c
cellmedi
immun
predispos
patient
sever
infect
mutat
innat
immunityassoci
gene
increas
risk
cmv
diseas
liver
transplant
express
innat
immun
cell
sens
glycoprotein
b
cmv
therebi
signal
immun
cell
produc
cytokin
antivir
peptid
studi
liver
transplant
recipi
genet
polymorph
gene
associ
higher
degre
cmv
replic
higher
incid
cmv
diseas
polymorph
decreas
cellular
recognit
cmv
cell
program
receptor
express
immun
evas
gene
also
assess
prognost
indic
cmv
diseas
follow
liver
transplant
cmv
diseas
liver
recipi
manifest
fever
bone
marrow
suppress
organinvas
diseas
direct
clinic
effect
classifi
ed
cmv
syndrom
fever
myelosuppress
tissueinvas
cmv
diseas
often
involv
gastrointestin
tract
cmv
gastriti
esophag
enter
coliti
although
organ
may
involv
cmv
hepat
common
liver
transplant
recipi
compar
solid
organ
transplant
recipi
manifest
symptom
indistinguish
acut
allograft
reject
avail
sensit
test
rapid
detect
cmv
blood
may
obviat
need
liver
biopsi
differenti
cmv
infect
reject
howev
mani
case
liver
biopsi
requir
differenti
demonstr
coexist
cmv
diseas
allograft
reject
sever
indirect
outcom
patient
mediat
abil
viru
modul
immun
system
cmv
known
potent
upregul
alloantigen
therebi
increas
risk
acut
reject
chronic
allograft
dysfunct
cmv
associ
vanish
bile
duct
syndrom
ductopen
reject
lead
chronic
cholestasi
allograft
failur
higher
incid
hepat
arteri
thrombosi
immunomodulatori
effect
cmv
predispos
opportunist
infect
includ
fungi
virus
bacteria
nocardia
cmvinfect
transplant
recipi
like
develop
ebvassoci
ptld
develop
coinfect
virus
human
herp
viru
associ
cmv
acceler
cours
hcv
recurr
describ
fortyeight
percent
hcvtransplant
patient
develop
cmv
diseas
allograft
loss
die
within
year
transplant
compar
patient
asymptomat
cmv
infect
develop
cmv
infect
cmv
infect
independ
predictor
mortal
solid
organ
transplant
use
anticmv
drug
either
antivir
prophylaxi
preemptiv
therapi
led
reduct
overal
mortal
solid
organ
transplant
analysi
liver
transplant
recipi
demonstr
cmv
diseas
occur
patient
occurr
independ
associ
fi
vefold
increas
risk
allcaus
mortal
increas
risk
infectionrel
mortal
allograft
reject
promot
cmv
reactiv
signifi
cant
risk
factor
cmv
diseas
follow
liver
transplant
cytokin
releas
acut
reject
particularli
potent
activ
latent
cmv
therapi
allograft
reject
involv
intensifi
cation
immunosuppress
regimen
increas
risk
cmv
diseas
risk
cmv
diseas
liver
transplant
associ
direct
proport
degre
cmv
replic
partli
function
overimmunosuppress
two
strategi
cmv
diseas
prevent
liver
transplant
preemptiv
therapi
antivir
prophylaxi
preemptiv
therapi
cmv
reactiv
monitor
sensit
assay
upon
detect
antivir
drug
administ
earli
halt
progress
asymptomat
infect
fullblown
clinic
diseas
preemptiv
therapi
oral
ganciclovir
intraven
ganciclovir
valganciclovir
result
reduct
cmv
diseas
unlik
antivir
prophylaxi
associ
lateonset
cmv
diseas
valganciclovir
current
commonli
use
drug
preemptiv
therapi
preemptiv
therapi
may
complet
effect
cmv
liver
transplant
recipi
replic
kinet
cmv
immun
defi
cient
individu
rapid
antivir
prophylaxi
antivir
drug
ganciclovir
valganciclovir
administ
patient
risk
cmv
diseas
liver
transplant
clear
consensu
regard
antivir
prophylaxi
administ
major
transplant
center
prevent
primari
cmv
diseas
highrisk
cmv
transplant
recipi
prophylaxi
recommend
cmv
liver
recipi
sever
clinic
trial
demonstr
effect
prevent
direct
indirect
effect
cmv
liver
transplant
compar
placebo
patient
receiv
antivir
prophylaxi
reduct
cmv
diseas
reduct
cmv
infect
use
acyclovir
anticmv
prophylaxi
liver
transplant
supplant
ganciclovir
valganciclovir
superior
effi
caci
prophylact
versu
preemptiv
therapi
intermediateand
lowrisk
group
dr
respect
base
local
expertis
transplant
center
howev
gener
approach
patient
seroneg
blood
product
use
prophylaxi
administ
dr
patient
monitor
cmv
reactiv
treat
preemptiv
day
avail
protect
match
donor
recipi
base
cmv
serolog
statu
advoc
shown
reduc
risk
posttranspl
cmv
diseas
current
recommend
antivir
treatment
cmv
diseas
liver
transplant
intraven
ganciclovir
along
reduct
degre
pharmacolog
immunosuppress
valganciclovir
possibl
oral
treatment
mild
moder
diseas
case
ganciclovirresist
cmv
diseas
treatment
option
includ
foscarnet
cidofovir
cmv
hyperimmun
globulin
lefl
unomid
compartment
cmv
diseas
refer
clinic
syndrom
wherein
viru
detect
affect
tissu
minim
detect
undetect
blood
gastrointestin
system
compartment
cmv
diseas
form
gastriti
esophag
enter
coliti
constitut
vast
major
tissueinvas
condit
herp
simplex
virus
commonli
infect
human
produc
wide
varieti
ill
clinic
manifest
cours
hsv
infect
depend
site
involv
patient
age
immun
statu
hsv
viremia
result
viscer
involv
affect
mainli
esophagu
lung
liver
liver
involv
occur
neonat
infect
pregnanc
immunocompromis
host
frequent
fulmin
diseas
hsv
uncommon
caus
hepat
immunocompet
patient
mild
asymptomat
elev
aminotransferas
level
detect
healthi
adult
genit
infect
fulmin
hepat
rise
aminotransferas
report
associ
favor
outcom
antivir
therapi
incid
hsv
hepat
report
fulmin
hepat
case
immunocompromis
host
hsv
hepat
occur
primari
rare
recurr
infect
triad
fever
leukopenia
markedli
elev
liver
enzym
well
thrombocytopenia
rel
mild
increas
bilirubin
liver
biopsi
essenti
establish
diagnosi
hsv
hepat
show
focal
sometim
extens
hemorrhag
coagul
necrosi
hepatocyt
limit
infl
ammatori
respons
typic
intranuclear
inclus
cowdri
type
often
identifi
ed
margin
foci
necrosi
diagnosi
confi
rmed
detect
hsv
dna
sequenc
molecular
techniqu
neonat
hepat
occur
multiorgan
involv
carri
high
mortal
rate
pregnant
women
observ
context
dissemin
primari
infect
third
trimest
present
fulmin
hepat
mucocutan
lesion
present
half
case
thu
mani
case
diagnos
autopsi
earli
diagnosi
treatment
antivir
therapi
may
revers
otherwis
fatal
process
treatment
choic
patient
earli
highdos
acyclovir
recurr
observ
suggest
dissemin
hsv
infect
absolut
contraind
transplant
certain
clinic
set
import
addit
human
herp
virus
debat
recent
year
accord
seri
patient
higher
rate
acut
chronic
allograft
reject
bacteri
opportunist
infect
higher
risk
cmv
diseas
shorter
graft
surviv
reactiv
common
solid
organ
transplant
clinic
diseas
rare
manifest
fever
myelosuppress
end
organ
diseas
includ
enceph
hepat
treatment
indic
end
organ
diseas
includ
foscarnet
ganciclovir
cidofovir
primari
varicella
infect
usual
benign
mild
transient
elev
liver
enzym
children
howev
caus
sever
acut
hepat
even
alf
immunecompet
adult
transplant
patient
primari
infect
present
aggress
liver
diseas
infect
may
occur
immedi
postop
period
sever
month
liver
transplant
usual
associ
rapid
onset
fatal
hepat
serolog
test
littl
valu
immunocompromis
patient
confi
rmation
diagnosi
made
isol
vzv
skin
lesion
affect
organ
liver
biopsi
often
show
foci
coagul
necrosi
intranuclear
inclus
infl
ammatori
respons
earli
administr
intraven
acyclovir
critic
set
vzv
hepat
especi
immunocompromis
patient
parvoviru
small
dna
viru
member
parvovirida
famili
clinic
manifest
includ
erythema
infectiosum
hydrop
fetali
fetal
death
children
arthriti
adult
leucopenia
thrombocytopenia
aplast
crisi
patient
chronic
hemolyt
anemia
addit
featur
rare
manifest
includ
neurolog
cardiac
hepat
end
organ
damag
vascul
hepat
manifest
rang
mild
transient
hepat
acut
liver
failur
without
associ
aplast
anemia
infect
usual
benign
selflimit
symptomat
therapi
alon
recommend
differ
serotyp
adenovirus
caus
acut
infect
respiratori
system
conjunctiva
gastrointestin
tract
occasion
hemorrhag
cystiti
infantil
diarrhea
intussuscept
central
nervou
system
infect
multiorgan
involv
report
immunocompromis
rare
immunocompet
patient
associ
increas
mortal
fatal
case
adenoviru
infect
fulmin
hepat
report
immunosuppress
adult
specifi
c
therapi
adenoviru
hepat
current
avail
cidofovir
recent
suggest
option
treatment
sever
virus
may
involv
liver
part
acut
viral
infect
tabl
infect
may
manifest
mild
hepat
rare
sever
hepat
liver
failur
along
sever
manifest
hemorrhag
fever
therapi
support
anecdot
report
support
antivir
therapi
patient
liver
failur
consid
urgent
liver
transplant
howev
may
hinder
concomit
damag
organ
